Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
GI Oncology Now
Bile Duct Cancer
Colorectal Cancer
Gastroesophageal Cancer
Gastric Cancer
GEP-NETs
GIST
Liver Cancer
Pancreatic Cancer
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Yvette C. Terrie
Yvette C. Terrie
Yvette C. Terrie
Articles by Yvette C. Terrie
Study Shows No Clinical Benefit Observed With Atezolizumab as Adjunctive Therapy for Triple Negative Breast Cancer
Yvette C. Terrie
Triple-Negative Breast Cancer
|
April 8, 2025
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Read More
Study Shows That Black Patients With Metastatic Breast Cancer Tend to Experience Higher Mortality Rates Than White Patients
Yvette C. Terrie
Breast Cancer News
|
April 6, 2025
Study finds somatic differences and lower PI3K inhibitor use in Black vs White patients with metastatic breast cancer.
Read More
Interim SERENA-6 Data: Camizestrant Significantly Improves PFS in First-Line HR+/HER2- Advanced Breast Cancer With ESR1 Mutations
Yvette C. Terrie
HR Breast Cancer
|
April 4, 2025
Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.
Read More